CIK 0001404644
- Non-accelerated filer
- Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 980542593
- Phone
- +1 877-237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-08-07 | BAKER BROS. ADVISORS LP Director | Purchase | +209,382 | $3.02 | $633K | 10,054,723 |
| 2019-08-07 | BAKER BROS. ADVISORS LP Director | Purchase | +4,564 | $3.15 | $14K | 1,200,520 |
| 2019-08-07 | BAKER BROS. ADVISORS LP Director | Purchase | +50,436 | $3.15 | $159K | 10,105,159 |
| 2019-08-06 | BAKER BROS. ADVISORS LP Director | Purchase | +855 | $2.83 | $2K | 1,170,550 |
| 2019-08-06 | BAKER BROS. ADVISORS LP Director | Purchase | +9,445 | $2.83 | $27K | 9,773,904 |
| 2019-08-06 | BAKER BROS. ADVISORS LP Director | Purchase | +5,932 | $2.85 | $17K | 1,176,482 |
| 2019-08-06 | BAKER BROS. ADVISORS LP Director | Purchase | +65,568 | $2.85 | $187K | 9,839,472 |
| 2018-08-07 | Main David President and CEO | Grant or award · Stock Option (Right to Buy) | +415,000 | 415,000 | ||
| 2018-08-07 | McCloskey Shelley VP, HR and Administration | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2018-08-07 | MacKenzie Lloyd Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +145,000 | 145,000 | ||
| 2018-08-07 | Alam Kamran CFO, Vice President Finance | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2018-05-14 | LEVITT DANIEL J Director | Option exercise | +3,906 | $10.56 | $41K | 3,906 |
| 2018-05-14 | LEVITT DANIEL J Director | Sale | −3,906 | $12.67 | $49K | 0 |
| 2018-05-14 | LEVITT DANIEL J Director | Option exercise · Stock Option (Right to Buy) | −3,906 | 0 | ||
| 2018-05-07 | BAKER BROS. ADVISORS LP Director | Grant or award · Non-Qualified Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2018-05-07 | SIMPSON TODD E Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2018-05-07 | Pelzer Robert Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2018-05-07 | Bridger Gary Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2018-05-07 | Nolan Sean P. Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2018-05-07 | LEVITT DANIEL J Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 |
Page 13 of 20 · 397 trades